INJECTABLE MICROBEADS FOR DELIVERY OF BUPRENORPHINE

Information

  • Research Project
  • 2123132
  • ApplicationId
    2123132
  • Core Project Number
    R43DA009746
  • Full Project Number
    1R43DA009746-01
  • Serial Number
    9746
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/1995 - 29 years ago
  • Project End Date
    12/31/1995 - 28 years ago
  • Program Officer Name
  • Budget Start Date
    7/1/1995 - 29 years ago
  • Budget End Date
    12/31/1995 - 28 years ago
  • Fiscal Year
    1995
  • Support Year
    1
  • Suffix
  • Award Notice Date
    6/30/1995 - 29 years ago
Organizations

INJECTABLE MICROBEADS FOR DELIVERY OF BUPRENORPHINE

The objective of this research program is to demonstrate the feasibility of a new controlled-release technology for use in an injectable formulation of buprenorphine to improve treatment of opioid dependence. The key to the new technology is the use of bioerodible microporous microbeads with a controllable structure that allows for high drug loadings as well as easily varied release rates and durations of release. These controlled-release microbeads would be used in an injectable formulation that would result in much-improved patient compliance, better efficacy, and fewer side effects than is the case with current therapies. Specific tasks in Phase l include identification of bioerodible polymers, preparation of candidate microporous microbeads, in vitro testing of drug- loaded microbeads, determination of short-term stability. and in vivo evaluation of candidate microbeads in rhesus monkeys. The feasibility of this approach will be demonstrated if the in vitro and in vivo tests indicate efficacy over 3- to 14-day time periods. If this is the case, a Phase Il program will be focused on further development of this technology and completion of preclinical studies necessary for submission of an Investigational New Drug application. PROPOSED COMMERCIAL APPLICATION: Successful development of this technology for injectable formulations of buprenorphine would lead to more effective treatment of opioid dependence. The same technology could also be useful for treatment of chronic pain, treatment of cocaine dependence, and delivery of peptide or oligonucleotide drugs, hormones, and vaccines.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R43
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    BEND RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    977018583
  • Organization District
    UNITED STATES